MACM
March Altus Capital Management Portfolio holdings
AUM
$16M
This Quarter Return
-8.76%
1 Year Return
+18.92%
3 Year Return
+153.93%
5 Year Return
–
10 Year Return
–
AUM
$17M
AUM Growth
+$17M
(-1.3%)
Cap. Flow
+$720K
Cap. Flow
% of AUM
4.24%
Top 10 Holdings %
Top 10 Hldgs %
86.05%
Holding
28
New
8
Increased
3
Reduced
3
Closed
14
Top Buys
| 1 |
Edwards Lifesciences
EW
|
$4.84M |
| 2 |
Gilead Sciences
GILD
|
$1.69M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$1.62M |
| 4 |
PETX
Aratana Therapeutics, Inc.
PETX
|
$935K |
| 5 |
MDCO
Medicines Co
MDCO
|
$838K |
Top Sells
| 1 |
Universal Health Services
UHS
|
$2.08M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$1.08M |
| 3 |
THOR
THORATEC CORPORATION
THOR
|
$1.05M |
| 4 |
United Therapeutics
UTHR
|
$985K |
| 5 |
CYNO
Cynosure, Inc. Class A
CYNO
|
$983K |
Sector Composition
| 1 | Healthcare | 81.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Edwards Lifesciences
EW
$47.8B
| $4.84M | 28.53% | +34,069 | New | +$4.84M |
|
|
2
Gilead Sciences
GILD
$140B
| $1.69M | 9.92% | +17,162 | New | +$1.69M |
|
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.62M | 9.51% | +48,825 | New | +$1.62M |
|
4
Eli Lilly
LLY
$657B
| $1.41M | 8.3% | 16,844 +1,106 | +7% | +$92.6K |
|
|
PETX
5
DELISTED
Aratana Therapeutics, Inc.
PETX
| $935K | 5.51% | +110,537 | New | +$935K |
|
6
DexCom
DXCM
$29.5B
| $841K | 4.95% | 9,794 -5,710 | -37% | -$490K |
|
|
MDCO
7
DELISTED
Medicines Co
MDCO
| $838K | 4.94% | +22,077 | New | +$838K |
|
8
Regeneron Pharmaceuticals
REGN
$61.5B
| $817K | 4.81% | 1,756 -538 | -23% | -$250K |
|
|
MNK
9
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $816K | 4.81% | 12,769 +4,592 | +56% | +$293K |
|
10
Incyte
INCY
$16.5B
| $810K | 4.77% | +7,344 | New | +$810K |
|
|
MDVN
11
DELISTED
MEDIVATION, INC.
MDVN
| $799K | 4.71% | +18,794 | New | +$799K |
|
12
Neurocrine Biosciences
NBIX
$13.8B
| $692K | 4.08% | 17,386 +8,793 | +102% | +$350K |
|
|
AERI
13
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $549K | 3.23% | +30,962 | New | +$549K |
|
|
14
United Therapeutics
UTHR
$13.8B
| $328K | 1.93% | 2,500 -7,509 | -75% | -$985K |
|
|
AGEN
15
Agenus
AGEN
$133M
| – | – | -18,517 | Closed | -$160K |
|
16
Cigna
CI
$80.3B
| – | – | -4,842 | Closed | -$784K |
|
17
Cencora
COR
$56.5B
| – | – | -6,707 | Closed | -$713K |
|
18
Catalyst Pharmaceutical
CPRX
$2.52B
| – | – | -80,890 | Closed | -$334K |
|
19
Humana
HUM
$36.5B
| – | – | -3,862 | Closed | -$739K |
|
20
Ultragenyx Pharmaceutical
RARE
$2.89B
| – | – | -3,299 | Closed | -$338K |
|
|
21
Universal Health Services
UHS
$11.6B
| – | – | -14,663 | Closed | -$2.08M |
|
22
Zoetis
ZTS
$69.3B
| – | – | -14,956 | Closed | -$721K |
|
|
ZLTQ
23
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| – | – | -18,165 | Closed | -$535K |
|
|
CYNO
24
DELISTED
Cynosure, Inc. Class A
CYNO
| – | – | -25,475 | Closed | -$983K |
|
|
THOR
25
DELISTED
THORATEC CORPORATION
THOR
| – | – | -23,486 | Closed | -$1.05M |
|